Transitions In The Trial Landscape: What Will Drive RCTs Into The Clinic?

Clinical trial execution is both a curse and a promise in the heated stakes for first-mover advantage in new drug development.  It’s a curse because siloed practices and legacy behaviors die hard – and it’s a promise because the volume of diverse data and a growing push for integration are finally closing the gap between research, evidence and the patient experience with disease.   New research from the Tufts University Center for the Study of Drug Development examines the struggle between these two forces and concludes that real change in the conduct of clinical trials is beginning to take root. 

The conduct of industry-sponsored clinical trials are at a critical juncture.